Introduction
============

*Acinetobacter baumannii* is one of the most important nosocomial pathogens associated with hospital-acquired infections worldwide and is the cause of serious infections including pneumonia, meningitis, bacteremia, and catheter-related urinary tract infections.[@b1-idr-11-2021],[@b2-idr-11-2021] *A. baumannii* is inherently difficult to eliminate by desiccation and disinfection, and resistance is emerging to many antibiotics.[@b3-idr-11-2021] *Acinetobacter* species are the fifth most common pathogens in intensive care units (ICUs) in 75 countries.[@b4-idr-11-2021] *A. baumannii* bloodstream infection (BSI) significantly extend hospital stay and increase mortality, with studies reporting an overall mortality rate of 29%--63%.[@b5-idr-11-2021]--[@b7-idr-11-2021] Overuse of invasive procedures, antibiotics, and steroids may have triggered the increase in *A. baumannii* BSI in recent years.[@b8-idr-11-2021]

Carbapenem antibiotics are the principal agents used in the treatment of *A. baumannii* infections.[@b9-idr-11-2021] Extensive use has, however, resulted in a rapid increase in the incidence of carbapenem-resistant *A. baumannii* (CRAB) especially in critical care. One study conducted in the USA indicated that carbapenem resistance increased from 20.6% in 2002 to 49.2% in 2008.[@b10-idr-11-2021] In China, isolates of *A. baumannii* increased from 9.2% in 2005 to 11.1% in 2014 and resistance of *A. baumannii* strains to carbapenems increased from 31% to 66.7% during this period.[@b11-idr-11-2021],[@b12-idr-11-2021] Higher bacterial resistance is associated with an increased patient morbidity and health care costs.[@b13-idr-11-2021],[@b14-idr-11-2021] Sulbactam, tigecycline, polymyxin, amino-glycosides, and rifampicin have been recommended for the treatment of CRAB infections, but these recommendations lack systematic and comprehensive research-based clinical evidence, and no large-scale clinical trials have been conducted to evaluate treatment approaches in patients with *A. baumannii* BSI.[@b15-idr-11-2021],[@b16-idr-11-2021]

In this retrospective analysis, we analyzed data from patients with confirmed *A. baumannii* BSI to identify risk factors associated with carbapenem resistance. We also aimed to improve the understanding of clinical manifestations, antimicrobial therapy, and patient mortality in order to identify potential approaches to improve infection control and clinical treatment.

Methods
=======

Inclusion criteria and study objectives
---------------------------------------

This study was conducted at the First Affiliated Hospital, College of Medicine, Zhejiang University, after receiving approval from the research ethics committee (Reference Number: 2017-699). This study did not directly interfere with the patients or show the medical record number, patients' name, or other personal information. There was no adverse effect on the rights of patients. Moreover, we keep patient' data confidentiality. Therefore, consent to review their medical records was not required by the Institutional Review Board. Patients evaluated in this study included those with *A. baumannii* BSI hospitalized from January 2012 to December 2015. BSIs were assessed by following the criteria proposed by the American agency, the Centers for Disease Control and Prevention (CDC). If patients had more than one episode of *A. baumannii*-BSI, only data from the first episode were included.

In this study, a three-part analysis was conducted ([Figure 1](#f1-idr-11-2021){ref-type="fig"}), which aimed to 1) identify risk factors associated with CRAB BSI, 2) explore the prognosis of *A. baumannii* BSI, and 3) assess the risk factors associated with the 28-day mortality. Patients were categorized as "survivors" if they were alive after 28 days of infection; otherwise, they were included in the nonsurvivor group. Patients whose treatment time was \<48 hours after BSI were excluded.

Data collection
---------------

Clinical data and laboratory results were collected from the hospital information system (HIS). The following data were collected: demographics, disease diagnosis, vital signs, laboratory reports at admission and infection, Acute Physiology and Chronic Health Evaluation II (APACHE II) score, invasive procedures prior to BSI, bacteriological examination, and use of antibiotics, steroids, and immunosuppressive agents before and after BSI.

Microbiological assessment and definition of terms
--------------------------------------------------

The identification and antimicrobial susceptibility of *A. baumannii* were determined using the VITEK 2 system (bio-Mérieux, Marcy-l' Etoile, France). Carbapenem resistance was defined as a minimum inhibitory concentration (MIC) of ≥8 µg/mL for imipenem and meropenem resistance by the breakpoints of the Clinical and Laboratory Standards Institute (CLSI) standards (2015).[@b17-idr-11-2021] Cefoperazone--sulbactam susceptibility was based on the breakpoints of ampicillin--sulbactam (MIC 16/8 µg/mL).[@b18-idr-11-2021] Tigecycline susceptibility was determined using the US Food and Drug Administration (FDA) breakpoints.[@b19-idr-11-2021] Methylprednisolone therapy was defined as \>20 mg/day administered for ≥7 days. Invasive procedure within 30 days prior to BSI was defined as invasive procedure used for ≥7 days within 30 days prior to BSI. Antimicrobial drug exposure was defined as the use of antibiotics for \>72 hours within the 14 days prior to *A. baumannii* BSI. Appropriate therapy was defined as the treatment of a systemic antibacterial agent that demonstrated in vitro activity against *A. baumannii* within the initial 72 hours after *A. baumannii* BSI diagnosis.

Statistical analysis
--------------------

SPSS Version 22.0 was used for the statistical analysis. The chi-squared and Fisher exact tests were used to analyze categorical variables. The Student's *t*-test and Wilcoxon rank sum test were used to analyze continuous variables. Variables with a *P*-value of \<0.05 in the univariate analysis were entered into a multivariate analysis using the multiple logistic regression method to determine the independent variables that were associated with carbapenem resistance and mortality. Variables with a *P*-value of \<0.05 were considered independent risk factors, and the results are presented as the ORs and 95% CIs. The Kaplan--Meier method was used to estimate the survival distribution function. All tests were two tailed, and a *P*-value of \<0.05 was considered statistically significant.

Results
=======

Patient's characteristics
-------------------------

Data from 293 patients with *A. baumannii* BSI were included, 201 (68.6%) of whom were male ([Table 1](#t1-idr-11-2021){ref-type="table"}). The mean age of the patients was 59.2±16.2 years; 99 (33.8%) patients were aged \>60 years ([Tables 1](#t1-idr-11-2021){ref-type="table"} and [S1](#SD1-idr-11-2021){ref-type="supplementary-material"}). Most patients (n=193, 65.9%) were diagnosed in the ICU ([Table S2](#SD2-idr-11-2021){ref-type="supplementary-material"}). Most patients (n=213, 72.7%) had underlying disease, the most common being hypertension, hepatitis/cirrhosis, and diabetes. Comorbid conditions occurred in 168 (57.3%) patients, the most common being pulmonary infection and septic shock. The mean APACHE II scores were 14.5±4.5 on admission and 18.8±5.8 at infection.

Bacterial isolates and drug susceptibility
------------------------------------------

Drug sensitivity testing showed that the resistance rates of *A. baumannii* to tigecycline, amikacin, and levofloxacin were low (10.0%, 28.6%, and 34.8% respectively), while the resistance rates of *A. baumannii* to cefepime, ciprofloxacin, imipenem, and piperacillin--tazobactam were high (82.9%, 81.9%, 82.6%, and 82.9% respectively; [Table S3](#SD3-idr-11-2021){ref-type="supplementary-material"}).

Risk factors associated with the development of carbapenem resistance
---------------------------------------------------------------------

Univariate analysis showed that invasive procedures, a previous ICU stay, in-hospital complications, and the use of methylprednisolone, antifungal drugs, and antibiotics were associated with CRAB. The results of multivariate logistic regression analysis showed that a previous ICU stay before BSI (OR =6.884, *P*=0.029), use of cefoperazone--sulbactam (OR =8.136, *P*=0.030), and use of carbapenem antibiotics (OR =10.432, *P*=0.004) within 30 days prior to BSI diagnosis were independent risk factors associated with carbapenem resistance ([Table 1](#t1-idr-11-2021){ref-type="table"}).

Risk factors for 28-day mortality in patients with *A. baumannii* BSI
---------------------------------------------------------------------

Of the 293 patients, 150 patients were classified as survivors and 86 patients were classified as nonsurvivors; 57 patients were excluded as their treatment time was \<48 hours. Multivariate logistic regression analysis showed that independent risk factors included ICU stay after BSI (OR =2.676, *P*=0.040), readmission within 90 days (OR =4.167, *P*=0.029), APACHE II score \>19 at infection (OR =2.998, *P*=0.012), use of tigecycline after BSI (OR =3.750, *P*=0.021), septic shock (OR =4.151, *P*=0.029), and multiple organ failure (OR =9.705, *P*=0.016). Appropriate treatment within 72 hours of BSI diagnosis was seen to be a protective factor (OR =0.254, *P*=0.011; [Table 2](#t2-idr-11-2021){ref-type="table"}).

As shown in [Table 2](#t2-idr-11-2021){ref-type="table"}, use of tigecycline after BSI was an independent risk factor for the 28-day mortality. When the 236 patients with *A. baumannii* BSI were divided into two groups based on treatment (nontigecycline therapy group \[n=137\] and tigecycline therapy \[n=99\]), the 28-day mortality of the nontigecycline group was lower than that of the tigecycline group (24.1% vs 53.5%, *P*=0.000) ([Table 2](#t2-idr-11-2021){ref-type="table"} and [Figure 2A](#f2-idr-11-2021){ref-type="fig"}). The APACHE II scores of the tigecycline group were higher than those of the nontigecycline group ([Table S4](#SD4-idr-11-2021){ref-type="supplementary-material"}), suggesting that, for a more serious infection, tigecycline was used more frequently. Patients were also divided into three subgroups based on the APACHE II score at infection (APACHE II scores ≤15, 16--25, and ≥26) to clarify the impact of infection severity on the outcome of those patients. Patients receiving nontigecycline therapy had lower mortality rates than those receiving tigecycline therapy in all the three APACHE score groups, with this difference being statistically significant in the subgroup with an APACHE II score of 16--25 (*P*=0.031; [Table 2](#t2-idr-11-2021){ref-type="table"}). Assessment of differences in daily dosage of tigecycline (\>0.1 and ≤0.1 g/day) did not change the mortality findings ([Figure 2B](#f2-idr-11-2021){ref-type="fig"}).

Risk factors for 28-day mortality in patients with CRAB BSI
-----------------------------------------------------------

A total of 186 patients (excluding 56 patients with CRAB BSI who died within 48 hours of diagnosis) were included in this analysis; 69.4% of patients stayed in the ICU after infection, and the 28-day mortality rate among these patients was 45.2%. Multivariate logistic regression analysis showed that the independent risk factors for the 28-day mortality included ICU stay after BSI (OR =2.649, *P*=0.036), APACHE II score \>19 at infection (OR =3.738, *P*=0.002), septic shock (OR =3.907, *P*=0.030), and multiple organ failure (OR =22.751, *P*=0.007) ([Table S5](#SD5-idr-11-2021){ref-type="supplementary-material"}).

Discussion
==========

*A. baumannii* can cause a variety of serious infections and has emerged as an important nosocomial pathogen globally. The detection rate of CRAB and the incidence of multidrug-resistant *A. baumannii* (MDRAB) and pan-drug-resistant *A. baumannii* (PDRAB) are increasing especially in critical patients, as are the associated patient mortality and medical care costs. Therefore, identifying approaches to limiting the development of resistance, as well as defining effective treatment regimens that can reduce patient mortality, are an urgent requirement.

In this study, an ICU stay and antimicrobial therapy before BSI were shown to be independent risk factors for CRAB. ICU patients are typically in a critical condition, have low immunity and high APACHE II scores, receive extensive antibiotic therapy, and undergo invasive procedures, making them susceptible to infection with CRAB.[@b20-idr-11-2021],[@b21-idr-11-2021]

Regarding the association between antibiotic use and *A. baumannii* resistance, one study found that the use of fluoro-quinolones, broad-spectrum cephalosporins, and carbapenems increased the risk of CRAB.[@b22-idr-11-2021] The present study showed that the use of cefoperazone--sulbactam and carbapenem antibiotics within the 30 days prior to BSI was independent risk factor for carbapenem resistance, that is, the first study to identify cefoperazone--sulbactam use as an independent risk factor for carbapenem resistance in *A. baumannii*. Sulbactam has activity against *A. baumannii* by binding to penicillin-binding protein 2 and has been recommended as a therapeutic agent to treat patients with *A. baumannii*-BSI,[@b23-idr-11-2021] while cefoperazone--sulbactam has been widely used to treat extended spectrum β-lactamase-producing enterobacterial and *A. baumannii* infections in China;[@b24-idr-11-2021] its use is not supported by any systematic evaluation of efficacy. However, due to the extensive use of this drug, the rate of *A. baumannii* resistance to cefoperazone--sulbactam has increased from 25.0% in 2004 to 37.7% in 2007 in China.[@b25-idr-11-2021] The association between cefoperazone--sulbactam use and bacterial resistance has not previously been analyzed, and our findings suggest that more attention should be paid to the resistance incurred from the use of cefoperazone--sulbactam and further evaluation is urgently required.

In this study, an ICU stay after BSI, septic shock, multiple organ failure, and APACHE II score \>19 at infection were shown to be risk factors for mortality, possibly indicating that the severity of the patient's disease was the main cause of death. Prognostic analysis showed that appropriate treatment within 72 hours was an independent protective factor for outcome. Previous reports show that effective drug therapy in the early stages is a key factor in survival.[@b8-idr-11-2021],[@b26-idr-11-2021] Erbay et al[@b27-idr-11-2021] showed that the mortality in patients receiving appropriate vs inappropriate antibiotic therapy within 48 hours is 39.5% vs 65%, respectively. We believed that appropriate antimicrobial treatment in the early stages is essential for *A. baumannii*-BSI patients.

CRAB BSI patients had more complications and more often died of critical illness. This study found that an ICU stay after BSI, APACHE II score \>19 at infection, septic shock, and multiple organ failure were risk factors for the 28-day mortality in these patients.

As the incidence of CRAB has increased in recent years, tigecycline has been widely used for the management of this infection. However, the use of tigecycline regimens to treat patients with *A. baumannii*-BSI is controversial.[@b28-idr-11-2021],[@b29-idr-11-2021] Some small studies report the clinical cure rate to be 80%,[@b30-idr-11-2021] while a range of other studies[@b31-idr-11-2021]--[@b33-idr-11-2021] show tigecycline regimens to be less effective in the treatment of patients with *A. baumannii* BSI. Drug safety guidelines published by the US FDA refer to an increased mortality risk associated with intravenous tigecycline compared with other drugs used to treat serious infections.[@b31-idr-11-2021] A meta-analysis of 14 randomized trials witĥ7,400 patients showed no benefit associated with tigecycline over standard antimicrobial agents for the treatment of serious infections, and the treatment success rate was lower with tigecycline than with control antibiotic agents.[@b32-idr-11-2021] Prasad et al[@b33-idr-11-2021] also found that tigecycline was associated with increased mortality (*P*=0.01) and noncure rates (*P*=0.01). In the present study, we found the use of tigecycline to be an independent risk factor for the 28-day mortality. By stratifying patients on the basis of APACHE II score, the mortality of the nontigecycline group was shown to be lower than that shown in patients treated with tigecycline in all APACHE II score subgroups, reaching statistical significance in patients with an APACHE II score of 16--25. We also demonstrated that a higher dose of tigecycline did not change the 28-day mortality trend. This result, in addition to data from previous studies, indicates that the use of tigecycline for the treatment of *A. baumannii* BSI should be considered with greater caution, despite this treatment approach being recommended by a Chinese consensus on the treatment of multidrug resistant (MDR) Gram-negative bacilli.[@b34-idr-11-2021] Although the underlying cause of higher mortality in trials of tigecycline is uncertain, inadequate antimicrobial activity in serum maybe an important reason. The standard dosing tigecycline regimen (100 mg load, followed by 50 mg every 12 hours) produces a maximum steady-state serum concentration of only 0.6 µg/mL.[@b35-idr-11-2021] In severe infections with high bacteremia risk, low serum levels combined with bacteriostatic rather than bactericidal activity may lead to an unfavorable microbiological response. Direct drug toxicity or other mechanisms cannot be completely eliminated also as possible contributors to the higher mortality observed with tigecycline.[@b33-idr-11-2021]

We acknowledge some limitations to this study. This was a retrospective study, and all patients with AB complex bacteremia treated at a single tertiary medical center during the study period were included in this study. Because the rate of CRAB, *A. baumannii* BSI treatment programs, and the use of tigecycline will differ in other hospitals, the study sample may not be broadly representative. However, to our knowledge, this is the largest cohort of patients with BSI caused by *A. baumannii* and is also the largest cohort of patients with BSI caused by CRAB. As such, the results can be used to facilitate the pre-emptive identification and targeting of patients who are at increased risk of CRAB and to evaluate optimal therapeutic approaches.

Conclusion
==========

This study showed that CRAB BSI was associated with higher levels of mortality, and an ICU stay and cefoperazone--sulbactam or carbapenem use were identified as risk factors associated with its emergence. Critical illness and tigecycline use significantly increased the mortality of patients with *A. baumannii* BSI. With a higher observed mortality rate, we suggest that tigecycline should be used with caution for the treatment of *A. baumannii* BSI.

Supplementary materials
=======================

###### 

Patients age distribution

  Patient's age (years)   Non-CRAB, n (%)   CRAB, n (%)
  ----------------------- ----------------- -------------
  0--18                   1 (2.0)           2 (0.8)
  18--60                  30 (58.8)         116 (47.9)
  61--75                  13 (25.5)         86 (35.5)
  \>75                    7 (13.7)          38 (15.7)
  Total                   51                242

**Abbreviation:** CRAB, carbapenem-resistant *Acinetobacter baumannii*.

###### 

Location of diagnosis department

  Diagnosis department                        Infection cases   Composition ratio (%)
  ------------------------------------------- ----------------- -----------------------
  ICU (internal medicine)                     70                23.9
  ICU (emergency)                             45                15.4
  ICU (surgical)                              41                14.0
  ICU (liver transplantation ward)            30                10.2
  ICU (negative pressure ward)                7                 2.4
  Hepatobiliary and pancreatic surgery ward   50                17.1
  Infection ward                              22                7.5
  Nephrology ward                             8                 2.7
  Emergency ward                              7                 2.4
  Neurosurgery ward                           5                 1.7
  Cardiothoracic surgery ward                 5                 1.7
  Hematology ward                             3                 1.2

**Abbreviation:** ICU, intensive care unit.

###### 

Drug susceptibility of *A. baumannii*

  Drug (strain number)             Sensitive    Intermediary   Resistance
  -------------------------------- ------------ -------------- ------------
  Ampicillin--sulbactam (293)      55 (18.8)    15 (5.1)       223 (76.1)
  Cefoperazone--sulbactam (174)    50 (28.7)    25 (14.4)      99 (56.9)
  Piperacillin--tazobactam (222)   36 (16.2)    2 (0.9)        184 (82.9)
  Cefepime (293)                   50 (17.1)    0              243 (82.9)
  Ceftazidime (293)                53 (18.1)    10 (3.4)       230 (78.5)
  Imipenem (293)                   51 (17.4)    0              242 (82.6)
  Ciprofloxacin (293)              53 (18.1)    0              240 (81.9)
  Levofloxacin (293)               67 (22.9)    124 (42.3)     102 (34.8)
  Amikacin (192)                   130 (67.7)   7 (3.7)        55 (28.6)
  Gentamicin (293)                 92 (31.4)    14 (4.8)       187 (63.8)
  Tobramycin (293)                 106 (36.2)   3 (1.0)        184 (62.8)
  Tigecycline (161)                120 (74.5)   25 (15.5)      16 (10.0)

**Abbreviation:** A. baumannii, Acinetobacter baumannii.

###### 

APACHE II score of nontigecycline group and tigecycline group in *A. baumannii*-BSI patients

  Antimicrobial regimen    *A. baumannii*-BSI patients   28-day mortality, n (%)   *P*-value   Mean APACHE II score at infection   *P*-value
  ------------------------ ----------------------------- ------------------------- ----------- ----------------------------------- -----------
  Nontigecycline therapy   137                           33 (24.1)                 \<0.05      16.16                               \<0.05
  Tigecycline therapy      99                            53 (53.5)                             19.32                               

**Abbreviations:** *A. baumannii, Acinetobacter baumannii*; APACHE II, Acute Physiology and Chronic Health Evaluation II.

###### 

Risk factors for 28-day mortality in patients with CRAB BSI

  Risk factor, n (%)                  Survival (n=102)   Nonsurvival (n=84)   Univariate analysis *P*-value   Multivariate logistic regression analysis   
  ----------------------------------- ------------------ -------------------- ------------------------------- ------------------------------------------- -------
  Age \>60 years                      47 (46.1)          49 (58.3)            0.096                                                                       
  Male                                73 (71.6)          51 (60.7)            0.118                                                                       
  ICU stay after BSI                  59 (57.8)          70 (83.3)            0.000                           2.649 (1.065--6.590)                        0.036
  Appropriate treatment               66 (64.7)          38 (45.2)            0.008                           0.439 (0.151--1.271)                        0.129
  Readmission within 90 days          74 (72.5)          75 (89.3)            0.004                           3.379 (0.971--11.756)                       0.056
  APACHE II score \>19 at diagnosis   22 (21.6)          52 (61.9)            0.000                           3.738 (1.623--8.609)                        0.002
  Drug use after BSI                                                                                                                                      
   Methylprednisolone                 41 (40.2)          47 (56.0)            0.032                           2.167 (0.911--5.154)                        0.080
   Tacrolimus                         15 (14.7)          4 (4.8)              0.046                           0.386 (0.086--1.744)                        0.216
   Fluoroquinolone antibiotics        22 (21.6)          10 (11.9)            0.082                                                                       
   Cefoperazone--sulbactam            54 (52.9)          43 (51.2)            0.812                                                                       
   Carbapenem antibiotics             62 (60.8)          48 (57.1)            0.615                                                                       
   Piperacillin--tazobactam           35 (34.3)          19 (22.6)            0.080                                                                       
   Tigecycline                        46 (45.1)          52 (61.9)            0.022                           2.129 (0.766--5.919)                        0.148
   \>2 types of antibiotics           51 (50.0)          43 (51.2)            0.872                                                                       
  Underlying disease                                                                                                                                      
   Hypertension                       41 (40.2)          35 (41.7)            0.839                                                                       
   Hepatitis/cirrhosis                22 (21.6)          17 (20.2)            0.824                                                                       
   Diabetes                           18 (17.6)          16 (19.0)            0.806                                                                       
   Renal insufficiency                23 (22.5)          14 (16.7)            0.317                                                                       
   Cardiac                            19 (18.6)          10 (11.9)            0.208                                                                       
   Respiratory                        17 (16.7)          12 (14.3)            0.656                                                                       
   Tumor                              6 (5.9)            5 (6.0)              0.984                                                                       
   Cerebrovascular                    5 (4.9)            2 (2.4)              0.369                                                                       
   \>1 underlying disease             42 (43.1)          26 (31.0)            0.150                                                                       
  Complication during hospital stay                                                                                                                       
   Pulmonary infection                33 (32.4)          28 (33.3)            0.887                                                                       
   Septic shock                       7 (6.9)            32 (38.1)            0.000                           3.907 (1.141--13.374)                       0.030
   Respiratory failure                11 (10.8)          14 (16.7)            0.242                                                                       
   MOF                                1 (1.0)            16 (19.5)            0.000                           22.751 (2.334--221.761)                     0.007
   Abdominal cavity infection         5 (4.9)            7 (8.3)              0.343                                                                       
   Stroke                             3 (2.9)            6 (7.1)              0.184                                                                       
   Gastrointestinal bleeding          1 (1.0)            6 (7.1)              0.028                           3.126 (0.270--36.208)                       0.362
   \>1 complication                   12 (11.8)          36 (42.9)            0.000                           1.521 (0.535--4.320)                        0.431

**Note:** Data are expressed as numbers (%) unless otherwise stated.

**Abbreviations:** APACHE II, Acute Physiology and Chronic Health Evaluation II; BSI, bloodstream infection; CRAB, carbapenem-resistant *Acinetobacter baumannii*; ICU, intensive care unit; MOF, multiple organ failure.
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![Flowchart of the case selection process.\
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![Kaplan--Meier survival estimates among patients with *A. baumannii*-BSI.\
**Notes:** (**A**) Treatment with or without tigecycline. (**B**) Tigecycline dose effect.\
**Abbreviations:** *A. baumannii, Acinetobacter baumannii*; BSI, bloodstream infection.](idr-11-2021Fig2){#f2-idr-11-2021}

###### 

Risk factors for carbapenem resistance in *Acinetobacter baumannii* bloodstream infections

  Risk factor, n (%)                              Non-CRAB (n=51)   CRAB (n=242)   Univariate analysis *P*-value   Multivariate logistic regression analysis   
  ----------------------------------------------- ----------------- -------------- ------------------------------- ------------------------------------------- -------
  Age \>60 years                                  20 (39.2)         124 (51.2)     0.199                           --                                          --
  Male                                            37 (72.5)         164 (67.8)     0.54                            --                                          --
  ICU stay prior to BSI                           3 (5.9)           163 (67.4)     0.000                           6.884 (1.215--39.015)                       0.029
  Hospital stay \>30 days prior to BSI            2 (3.9)           74 (30.6)      0.000                           2.904 (0.298--28.317)                       0.359
  Readmission within 90 days                      42 (82.4)         199 (82.2)     0.984                           --                                          --
  APACHE II score \>15 at admission               5 (9.8)           115 (47.5)     0.000                           3.812 (0.875--16.605)                       0.075
  Surgical operation                              17 (33.3)         101 (41.7)     0.266                           --                                          --
  Invasive procedure within 30 days prior to BS   I                                                                                                            
   Tracheotomy                                    2 (3.9)           47 (19.4)      0.007                           1.909 (0.211--17.258)                       0.565
   Mechanical ventilation                         10 (19.6)         202 (83.5)     0.000                           1.236 (0.217--7.045)                        0.811
   Central venous catheterization                 11 (21.6)         204 (84.3)     0.000                           3.374 (0.621--18.348)                       0.159
   Pulmonary artery catheterization               6 (11.8)          158 (65.3)     0.000                           1.745 (0.310--9.822)                        0.528
   Urinary catheterization                        13 (25.5)         211 (87.2)     0.000                           2.611 (0.420--16.238)                       0.303
   Gastric tube indwelling                        10 (19.6)         189 (78.1)     0.000                           0.917 (0.167--5.049)                        0.921
   Chest drainage                                 6 (11.8)          47 (19.4)      0.197                           --                                          --
   Abdominal drainage                             7 (13.7)          77 (31.8)      0.009                           1.672 (0.357--7.819)                        0.514
   Hemodialysis                                   2 (3.9)           65 (26.9)      0.000                           1.335 (0.099--17.943)                       0.828
   Sputum aspiration                              6(11.8)           108(44.6)      0.000                           1.729 (0.304--9.816)                        0.537
   More than four procedures                      7 (13.7)          203 (83.9)     0.000                           0.764 (0.072--8.123)                        0.823
  Drug use in the 30 days prior to BSI                                                                                                                         
   Methylprednisolone                             5 (9.8)           116 (47.9)     0.000                           4.279 (0.854--21.446)                       0.077
   Tacrolimus                                     3 (5.9)           33 (13.6)      0.125                           --                                          --
   Antifungal                                     2 (3.9)           76 (31.4)      0.000                           1.618 (0.170--15.385)                       0.675
   Fluoroquinolone antibiotics                    4 (7.8)           51 (21.1)      0.028                           2.920 (0.459--18.574)                       0.256
   Cephalosporin antibiotics                      9 (17.6)          43 (17.8)      0.984                           --                                          --
   Tigecycline                                    1 (2.0)           34 (14.0)      0.016                           3.408 (0.230--50.534)                       0.373
   Cefoperazone--sulbactam                        3 (5.9)           62 (25.6)      0.000                           8.136 (1.230--53.800)                       0.030
   Carbapenem antibiotic                          4 (7.8)           165 (68.2)     0.000                           10.432 (2.079--52.358)                      0.004
   Piperacillin--tazobactam                       4 (7.8)           79 (32.6)      0.000                           1.253 (0.238--6.595)                        0.790
  Underlying disease                                                                                                                                           
   Hypertension                                   14 (27.5)         94 (38.8)      0.125                           --                                          --
   Hepatitis/cirrhosis                            12 (23.5)         58 (24.0)      0.947                           --                                          --
   Diabetes                                       3 (5.9)           50 (20.7)      0.013                           2.585 (0.277--24.127)                       0.405
   Renal insufficiency                            4 (7.8)           48 (19.8)      0.145                           --                                          --
   Cardiac                                        5 (9.8)           31 (12.8)      0.552                           --                                          --
   Respiratory                                    3 (5.9)           23 (9.5)       0.408                           --                                          --
   Tumor                                          2 (3.9)           15 (6.2)       0.527                           --                                          --
   Cerebrovascular diseases                       2 (3.9)           10 (4.1)       0.945                           --                                          --
   \>1 kind of underlying disease                 9 (17.6)          86 (35.5)      0.013                           1.410 (0.371--5.364)                        0.614
  Comorbid conditions                                                                                                                                          
   Pulmonary infection                            7 (13.7)          83 (34.3)      0.004                           1.468 (0.335--6.429)                        0.611
   Septic shock                                   2 (3.9)           63 (26.0)      0.001                           4.480 (0.313--64.140)                       0.269
   MOF                                            2 (3.9)           33 (13.6)      0.052                           --                                          --
   Abdominal cavity infection                     4 (7.8)           14 (5.9)       0.578                           --                                          --
   Stroke                                         1 (2.0)           12 (3.3)       0.345                           --                                          --
   Gastrointestinal bleeding                      2 (3.9)           8 (3.3)        0.826                           --                                          --
   \>1 complication                               5 (9.8)           77 (31.8)      0.001                           1.393 (0.177--10.966)                       0.753

**Notes:** Data are expressed as numbers (%) unless otherwise stated. CVC: catheter placed in the internal jugular vein or subclavian vein or groin femoral vein. Pulmonary artery catheterization: catheter placed in the pulmonary artery; it is used to detect heart failure or sepsis, monitor therapy, and evaluate the effects of drugs. Sputum aspiration: sucking the secretions of the respiratory tract by mouth, nasal cavity, and artificial airway (tracheostomy) to keep the airway open and prevent complications such as inhalation pneumonia, atelectasis, and asphyxia. "--"*P*\<0.05 in the univariate analysis were entered into a multivariate analysis; *P*≥0.05 in the univariate analysis were not entered into a multivariate analysis.

**Abbreviations:** APACHE II, Acute Physiology and Chronic Health Evaluation II; BSI, bloodstream infection; CRAB, carbapenem-resistant *Acinetobacter baumannii*; CVC, central venous catheter; ICU, intensive care unit; MOF, multiple organ failure.

###### 

Risk factors for 28-day mortality in patients with *A. baumannii*-BSI

  Risk factor, n (%)                  Survivors (n=150)   Nonsurvivors (n=86)   Univariate analysis, *P*-value   Multivariate logistic regression analysis   
  ----------------------------------- ------------------- --------------------- -------------------------------- ------------------------------------------- -------
  Age \>60 years                      68 (45.3)           54 (62.8)             0.010                            1.329 (0.569--3.106)                        0.511
  Male                                108 (72.0)          53 (61.6)             0.100                            --                                          --
  Carbapenem resistance               102 (68.0)          84 (97.7)             0.000                            4.966 (0.569--41.365)                       0.138
  ICU stay after BSI                  59 (39.3)           72 (83.7)             0.000                            2.676 (1.045--6.851)                        0.040
  Appropriate antibiotic treatment    112 (74.7)          40 (46.5)             0.000                            0.254 (0.088--0.734)                        0.011
  Readmission within 90 days          113 (75.3)          77 (89.5)             0.008                            4.167 (1.158--14.993)                       0.029
  APACHE II score \>19 at diagnosis   22 (14.7)           53 (61.6)             0.000                            2.998 (1.269--7.085)                        0.012
  Drug use after BSI                                                                                                                                         
   Methylprednisolone                 48 (32.0)           48 (55.8)             0.000                            2.277 (0.960--5.402)                        0.062
   Tacrolimus                         19 (12.7)           4 (4.7)               0.046                            0.258 (0.057--1.169)                        0.079
   Fluoroquinolone                    27 (18.0)           12 (14.0)             0.295                            --                                          --
   Cefoperazone--sulbactam            67 (44.7)           43 (50.0)             0.429                            --                                          --
   Carbapenem                         72 (48.0)           50 (58.1)             0.013                            1.942 (0.748--5.038)                        0.173
   Tigecycline                        46 (30.7)           53 (61.6)             0.000                            3.750 (1.216--11.564)                       0.021
   APACHE II ≤15                      16 (10.7)           3 (3.5)               0.148                            --                                          --
   APACHE II ≥16 and ≤25              26 (17.3)           38 (44.2)             0.031                            --                                          --
   APACHE II ≥26                      4 (2.7)             12 (14.0)             0.858                            --                                          --
   \>2 types of antibiotic            56 (37.3)           44 (51.2)             0.039                            1.387 (0.507--3.795)                        0.524
  Underlying disease                                                                                                                                         
   Hypertension                       55 (36.7)           35 (40.7)             0.539                            --                                          --
   Hepatitis/cirrhosis                33 (22.0)           18 (20.9)             0.670                            --                                          --
   Diabetes                           21 (14.0)           16 (18.6)             0.349                            --                                          --
   Renal insufficiency                28 (18.7)           14 (16.3)             0.644                            --                                          --
   Coronary                           23 (15.3)           11 (12.8)             0.592                            --                                          --
   Respiratory                        20 (13.3)           13 (15.1)             0.704                            --                                          --
   Tumor                              10 (6.7)            5 (5.8)               0.796                            --                                          --
   Cerebrovascular                    7 (4.7)             2 (2.3)               0.366                            --                                          --
   \>1 underlying disease             53 (35.3)           26 (30.2)             0.424                            --                                          --
  Comorbid conditions                                                                                                                                        
   Pulmonary infection                39 (26.0)           29 (33.7)             0.208                            --                                          --
   Septic shock                       7 (4.7)             33 (38.4)             0.000                            4.151 (1.156--14.901)                       0.029
   Respiratory failure                11 (7.3)            15 (17.4)             0.017                            1.473 (0.387--5.611)                        0.570
   MOF                                2 (1.3)             16 (18.6)             0.000                            9.705 (1.520--61.970)                       0.016
   Abdominal cavity infection         9 (6.0)             7 (8.1)               0.529                            --                                          --
    Stroke                            3 (2.0)             7 (8.1)               0.024                            5.083 (0.757--34.139)                       0.094
   Gastrointestinal bleeding          2 (1.3)             7 (8.1)               0.009                            3.793 (0.456--31.561)                       0.217
   \>1 complication                   14 (9.3)            38 (44.2)             0.000                            1.642 (0.465--5.794)                        0.441

**Notes:** Data are expressed as number (%) unless otherwise stated. "--"*P*\<0.05 in the univariate analysis were entered into a multivariate analysis; *P*≥0.05 in the univariate analysis were not entered into a multivariate analysis.

**Abbreviations:** *A. baumannii, Acinetobacter baumannii;* APACHE II, Acute Physiology and Chronic Health Evaluation II; BSI, bloodstream infection; ICU, intensive care unit; MOF, multiple organ failure;.
